Company news

Enveric Biosciences, Inc. news

Latest news releases, newest first. Pick a year for every news release, call and deck from that year.

View company

Enveric Biosciences Reports Positive Results from Animal Studies Demonstrating Oral Bioavailability and Well Tolerated Side Effect Profile for EB-373

July 16, 2023

Enveric Biosciences Announces Development of Phase 1-Ready Formulation for EB-373 and Initiation of Scaled Up Manufacturing

June 25, 2023

Enveric Biosciences Announces Two Poster Presentations at the Canadian Chemistry Conference and Exhibition (CSC 2023)

June 6, 2023

Enveric Biosciences Receives Notice of Allowance from USPTO for EVM301 Series of Drug Candidates

June 4, 2023

Enveric Biosciences Announces Poster Presentation at Canadian Neuroscience Meeting 2023

May 29, 2023

Enveric Biosciences Receives Notice of Allowance From USPTO for C4-Carboxylic Acid-Substituted Tryptamine Derivatives for Next Generation Psilocin Prodrug

May 23, 2023

Enveric Biosciences Receives Notice of Allowance from USPTO for Novel Prodrug of Psilocin

May 17, 2023

Enveric Biosciences Reports First Quarter 2023 Financial Results and Operational Highlights

May 14, 2023

Enveric Biosciences Reports Fourth Quarter and Year-End 2022 Corporate and Financial Results

April 2, 2023

Enveric Biosciences Selects Australian CRO, Avance Clinical, in Preparation for Phase 1 Study of EB-373

March 22, 2023

Enveric Biosciences Establishes Australia-based Subsidiary to Accelerate its Lead Psilocin Prodrug Program Targeting Mental Health Indications

March 20, 2023

Enveric Biosciences Announces Bioproduction Platform Using Novel Cane Toad Enzyme for Psychedelic-Inspired Drug Discovery

March 13, 2023

Enveric Biosciences Appoints Kevin Coveney as Chief Financial Officer, and Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)

February 27, 2023

Enveric Biosciences Names Lynn Gallant Vice President, Clinical Operations, and Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)

February 22, 2023

Enveric Biosciences Announces Confidential Submission of Registration Statement for the Spin-off of its Cannabinoid Business to Shareholders

November 27, 2022

Enveric Biosciences Announces Poster Presentations of Lead Programs at the 2022 International Neurology & Brain Disorders Conference

October 11, 2022

Enveric Biosciences Appoints New Independent Directors

July 26, 2022

Enveric Biosciences Announces Closing of $8 Million Registered Direct and Private Placement Offerings, Priced at a Premium to Market Under Nasdaq Rules

July 25, 2022

Enveric Biosciences Announces $8 Million Registered Direct Offering and Private Placement, Priced at a Premium to Market Under Nasdaq Rules

July 24, 2022

Enveric Biosciences Announces Formation of Scientific Advisory Board to Drive Further Growth of Next-Generation Mental Health Medicines

July 18, 2022

Enveric Biosciences Announces Plans to Spin-off and Dividend its Cannabinoid Pipeline to Shareholders

May 10, 2022

Enveric Biosciences Announces Distribution of Series C Preferred Stock to Holders of its Common Stock

May 2, 2022

Enveric Biosciences Reports Full-Year 2021 Financial Results and Provides Business Update

March 30, 2022

Enveric Biosciences Expands Portfolio of Drug Development Candidates and Files New Provisional Patent Application

March 28, 2022

Enveric Biosciences Announces Publication of Four Patent Applications for Psychedelic-Inspired Drug Candidates

March 14, 2022

Enveric Biosciences Announces Closing of $10 Million Public Offering

February 14, 2022

Enveric Biosciences Announces Pricing of $10 Million Public Offering

February 10, 2022

Enveric Biosciences Announces Proposed Public Offering

February 9, 2022

Enveric Biosciences Announces Successful Synthesis and Filing of Provisional Patent for EV104 - Cannabinoid + Celecoxib Conjugate

February 7, 2022

Enveric Biosciences Appoints Dr. Bob Dagher as Chief Medical Officer

December 5, 2021

Enveric Biosciences Announces Positive Preclinical Data for EV102 Radiodermatitis Drug Candidate

November 17, 2021

Enveric Biosciences Announces Inclusion in AdvisorShares Psychedelics ETF

November 7, 2021

Enveric Biosciences Announces Artificial Intelligence Platform, PsyAI™, Has Identified Viable Drug Candidates from its 'Psybrary' of Psychedelic Molecular Compounds

October 4, 2021

Enveric Biosciences Announces Closing of MagicMed Industries Acquisition

September 16, 2021

Enveric Biosciences Announces Approval from Israel's Ministry of Health to Begin its Phase 1/2 Trial of Triple-Combination CBD Treatment for Glioblastoma

July 7, 2021

Enveric Biosciences Announces Definitive Agreement to Acquire MagicMed Industries, a Pharmaceutical Drug Discovery and Development Platform Focused on New-Generation Psychedelic Molecular Compounds and Derivatives

May 23, 2021

Enveric Biosciences Reports First Quarter 2021 Financial Results

May 17, 2021

Enveric Biosciences Appoints Dr. Arash Asher to Scientific Advisory Board

May 11, 2021

Enveric Biosciences Appoints Carter Ward as Chief Financial Officer

April 11, 2021

Enveric Biosciences Reports Full Year 2020 Financial Results and Provides Shareholder Update on its Accomplishments in 2021

March 31, 2021

Enveric Biosciences Appoints Dr. Douglas D. Lind to Company's Board of Directors

March 17, 2021

Enveric Biosciences Signs Definitive Agreement to Acquire Exclusive License for Novel Molecules from Diverse Biotech

March 9, 2021

Enveric Biosciences Launches Development Collaboration and Supply Agreement with PureForm Global to Support Cannabinoid Clinical Programs

February 24, 2021

Enveric Biosciences Inc. Announces Closing of $12.8 Million Registered Direct Offering of Common Stock

February 11, 2021

Enveric Biosciences Inc. Announces $12.8 Million Registered Direct Offering

February 8, 2021

Enveric Biosciences Inc. Announces Closing of $10 Million Registered Direct Offering

January 14, 2021

Enveric Biosciences Inc. Announces $10 Million Registered Direct Offering Priced At-the-Market under Nasdaq Rules

January 11, 2021

Enveric Biosciences Appoints Dr. Marcus Schabacker to Board of Directors

January 4, 2021

← Newer news releases

Decks

The 5 newest of 15 decks. Every deck is listed under its year.